Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
Quick facts
Marketed products
- CYCLOSPORINE VS INFLIXIMAB · Immunology / Gastroenterology
This is a comparative study evaluating cyclosporine (a calcineurin inhibitor) versus infliximab (a TNF-alpha inhibitor) for inflammatory bowel disease. - Infliximab CT-P13
- Mirikizumab - IV · Immunology / Gastroenterology
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut. - Mirikizumab - SC · Immunology / Gastroenterology
Mirikizumab is a monoclonal antibody that selectively inhibits IL-23 signaling by binding to the p19 subunit of IL-23, reducing inflammatory responses in the gut. - Start adalimumab in monotherapy · Immunology / Gastroenterology
Adalimumab is a monoclonal antibody that binds to and neutralizes tumor necrosis factor-alpha (TNF-α), reducing inflammatory signaling.
Phase 3 pipeline
- Azathioprine OR Mesalazine · Gastroenterology / Immunology
This is a combination therapy study comparing azathioprine (an immunosuppressant) and mesalazine (an anti-inflammatory) for inflammatory bowel disease.
Phase 2 pipeline
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives portfolio CI brief
- Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives pipeline updates RSS
Frequently asked questions about Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives
What are Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives's marketed drugs?
Top marketed products include CYCLOSPORINE VS INFLIXIMAB, Infliximab CT-P13, Mirikizumab - IV, Mirikizumab - SC, Start adalimumab in monotherapy.
What is Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives's pipeline?
Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives has 1 drugs in Phase 3, 2 in Phase 2, 0 in Phase 1. Late-stage candidates include Azathioprine OR Mesalazine.
Related
- CYCLOSPORINE VS INFLIXIMAB · Immunology / Gastroenterology
- Infliximab CT-P13
- Mirikizumab - IV · Immunology / Gastroenterology
- Mirikizumab - SC · Immunology / Gastroenterology
- Start adalimumab in monotherapy · Immunology / Gastroenterology
- Sector hub: All tracked pharma companies